Evidence map›Paper›PMID 41051985›Full record

ReviewJournal of feline medicine and surgery2025

Clinical therapeutics in feline medicine: updates for old and new drugs.

Isabella R Susi, Katrina Viviano, William H Whitehouse

Abstract readReview
In one paragraph

Review in Journal of feline medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Katrina VivianoSchool of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0002-1405-1306
William H WhitehouseCollege of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.ORCID 0000-0002-6080-2684

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

practical relevanceOver the past 10 years, feline medicine has significantly advanced through the addition of new pharmaceuticals and alternative formulations available for cats, as well as improvements in the knowledge about existing agents. Through continued drug development, the therapeutic options for cats are expanding. CLINICAL CHALLENGES: There are many speciesspecific clinical challenges encountered with the treatment of feline diseases. Additionally, therapeutic options can vary based on geography and change over time. EVIDENCE BASE: This review article discusses the current evidence for some of the newer therapeutic agents that are either presently available for use by feline medicine practitioners or are in development and undergoing clinical trials. Their recent introduction means the evidence for some of these medications is still emerging. The clinical use of these agents, available pharmacokinetic and pharmacodynamic data, and reported adverse effects in cats are presented. AUDIENCE: The information in this article is relevant to all veterinarians who practice feline medicine.

Indexed as

Cat DiseasesVeterinary DrugsAnimalsCatsVeterinary DrugsbexagliflozinBuprenorphinecapromorelinfrunevetmabgabapentinGS-441524molidustatpregabalinrapamycinremdesivirrivaroxabantamsulosintelmisartanvelagliflozin

Identifiers

PMID41051985
PMCPMC12501467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.